Boston Scientific (BSX) reported $5.07 billion in revenue for the quarter ended September 2025, representing a year-over-year increase of 20.3%. EPS of $0.75 for the same period compares to $0.63 a year ago.
The reported revenue compares to the Zacks Consensus Estimate of $4.97 billion, representing a surprise of +1.94%. The company delivered an EPS surprise of +5.63%, with the consensus EPS estimate being $0.71.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Boston Scientific performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Geographic Revenue- Rest of the World: $1.77 billion compared to the $1.76 billion average estimate based on three analysts. The reported number represents a change of +9.6% year over year.
- Geographic Revenue- U.S.: $3.29 billion versus the three-analyst average estimate of $3.21 billion. The reported number represents a year-over-year change of +27%.
- Net Sales- Cardiovascular- Peripheral Interventions- International: $297 million versus the two-analyst average estimate of $304.52 million. The reported number represents a year-over-year change of +4.2%.
- Net Sales- MedSurg- Neuromodulation- United States: $230 million versus $218.5 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +9% change.
- Net Sales- MedSurg- Worldwide: $1.72 billion versus the six-analyst average estimate of $1.7 billion. The reported number represents a year-over-year change of +16.5%.
- Net Sales- Cardiovascular- Worldwide: $3.34 billion versus $3.27 billion estimated by six analysts on average. Compared to the year-ago quarter, this number represents a +22.4% change.
- Net Sales- Cardiovascular- Cardiology- Worldwide: $2.64 billion versus the five-analyst average estimate of $2.57 billion. The reported number represents a year-over-year change of +24.1%.
- Net Sales- Cardiovascular- Peripheral Interventions- Worldwide: $702 million versus the five-analyst average estimate of $697.63 million. The reported number represents a year-over-year change of +16.6%.
- Net Sales- MedSurg- Endoscopy- Worldwide: $747 million compared to the $726.77 million average estimate based on five analysts. The reported number represents a change of +10.2% year over year.
- Net Sales- MedSurg- Neuromodulation- Worldwide: $293 million versus the five-analyst average estimate of $281.69 million. The reported number represents a year-over-year change of +9.3%.
- Net Sales- MedSurg- Urology- Worldwide: $682 million versus the five-analyst average estimate of $692.15 million. The reported number represents a year-over-year change of +28.2%.
- Net Sales- Cardiovascular- Cardiac Rhythm Management (CRM)- Worldwide: $578 million versus the four-analyst average estimate of $576.68 million. The reported number represents a year-over-year change of +3%.
View all Key Company Metrics for Boston Scientific here>>>
Shares of Boston Scientific have returned +2.3% over the past month versus the Zacks S&P 500 composite's +1.1% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Boston Scientific Corporation (BSX): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
